Forsythiaside Attenuates Lipopolysaccharide-induced Inflammatory Responses in the Bursa of Fabricius of Chickens by Downregulating the NF-κB Signaling Pathway
Overview
Affiliations
Forsythiaside, a phenylethanoside product isolated from air-dried fruits of , has been demonstrated to exhibit antioxidant, antibacterial and anti-inflammatory activities . However, its mechanism and the effects of lipopolysaccharide (LPS)-induced injury on the bursa of Fabricius (BF) of chickens are poorly understood. The present study aimed to investigate the anti-inflammatory effects of forsythiaside on LPS-induced acute inflammation. In addition, the potential molecular mechanisms of forsythiaside were analyzed in the BF, a special immune organ in chickens. Forty 15-day-old chickens were randomly divided into control, LPS and LPS plus forsythiaside (30 or 60 mg/kg) groups (n=10 for each group). In the LPS plus forsythiaside (30 or 60 mg/kg) groups, the chickens were orally administered with forsythiaside at doses of 30 and 60 mg/kg for seven days. At 21 days old, the chickens were intravenously injected with 200 μg/kg body weight LPS. Chickens in the control and LPS groups were only administered with vehicle or LPS, respectively, at day 21. At 3 h post-injection, the body temperature and nitric oxide (NO) levels were analyzed. In addition, the levels and mRNA expression of pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and IL-1β, and the mRNA expression of nuclear factor-κB (NF-κB), cyclooxygenase-2 (COX-2) and inducible NO synthase (iNOS), were examined in the BFs isolated from the chickens. The results revealed that forsythiaside was able to attenuate the LPS-induced inflammatory responses in the BFs of the chickens. The mechanisms by which forsythiaside exerted its anti-inflammatory effect were found to correlate with the inhibition of IL-6, IL-1β, TNF-α and COX-2 production, via the inactivation of NF-κB, indicating that the NF-κB-iNOS-NO signaling pathway may be important in this process.
Ghasemi-Dehnoo M, Amini-Khoei H, Lorigooini Z, Anjomshoa M, Bijad E, Rafieian-Kopaei M Inflammopharmacology. 2023; 32(1):795-808.
PMID: 38095803 DOI: 10.1007/s10787-023-01387-7.
Ghasemi-Dehnoo M, Lorigooini Z, Amini-Khoei H, Sabzevary-Ghahfarokhi M, Rafieian-Kopaei M Immun Inflamm Dis. 2023; 11(8):e926.
PMID: 37647443 PMC: 10408368. DOI: 10.1002/iid3.926.
Ikeda T, Kondo H, Nunomura D, Sato G, Ito M, Yamanaka N Antibiotics (Basel). 2023; 12(8).
PMID: 37627761 PMC: 10451233. DOI: 10.3390/antibiotics12081341.
Chen Y, Wei W, Fu J, Zhang T, Zhao J, Ma T BMC Complement Med Ther. 2023; 23(1):35.
PMID: 36737765 PMC: 9896724. DOI: 10.1186/s12906-023-03855-7.
Cellular mechanism of action of forsythiaside for the treatment of diabetic kidney disease.
Xu C, Miao H, Chen X, Zhang H Front Pharmacol. 2023; 13:1096536.
PMID: 36712665 PMC: 9880420. DOI: 10.3389/fphar.2022.1096536.